We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Desipramine in Infantile Neuroaxonal Dystrophy (INAD).

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03726996
Recruitment Status : Terminated (Funding exhausted)
First Posted : November 1, 2018
Results First Posted : October 14, 2020
Last Update Posted : October 14, 2020
Information provided by (Responsible Party):
Duke University

Brief Summary:

This is a research study to find out if clinically prescribed desipramine is effective at improving the symptoms and slowing the progression of Infantile Neuroaxonal Dystrophy (INAD) in affected children.

Participants will receive an initial oral dose of study drug once a day. This dose may be changed depending on response to study drug Clinically collected data will be recorded for up to 5 years. Investigators will also ask for participant permission to obtain a sample of child's skin biopsy from unused clinical sample previously collected for standard of care.

Condition or disease Intervention/treatment Phase
Infantile Neuroaxonal Dystrophy Drug: Desipramine Phase 4

Detailed Description:

To be eligible participants must be able to swallow tablets The study drug is to be taken once daily Schedule of events. Day 0 - ECG and blood tests (4 ml or ¾ teaspoon) Day 3 - ECG and blood tests (4 ml or ¾ teaspoon) Day 7 - ECG and blood tests (4 ml or ¾ teaspoon) Weeks 2, 3, 4, 8 & 12. ECG and blood tests (4 ml or ¾ teaspoon) Every 3 months for up to 5 years.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Novel Off-label Use of Desipramine in Infantile Neuroaxonal Dystrophy: Targeting the Sphingolipid Metabolism Pathway to Reduce Accumulation of Ceramide.
Actual Study Start Date : January 14, 2019
Actual Primary Completion Date : August 30, 2019
Actual Study Completion Date : August 30, 2019

Arm Intervention/treatment
Experimental: Children with INAD
Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality.
Drug: Desipramine
Study drug (desipramine) provided in tablet form to be taken daily.

Primary Outcome Measures :
  1. Change in Gross Motor Function as Measured by Gross Motor Function Measure (GMFM-66) [ Time Frame: Baseline, 3, 6, 9, and 12 months ]
    The Gross Motor Function Measure (GMFM-66) is a 66 item standardized observational instrument designed and validated to measure change in gross motor function over time in children with cerebral palsy. Items are ordered in terms of difficulty and a unit of change has the same meaning throughout the scale ranging from 0 to 100. 0 = does not initiate, 1 = initiates, 2 = partially completes, 3 = completes. Scoring the GMFM-66 requires the use of a computer program called the Gross Motor Ability Estimator (GMAE). Individual item scores are entered and a mathematical algorithm calculates an interval level total score. The total score is an estimate of the child's gross motor function.

  2. Change in Motor Function as Measured by Quick Motor Function Test (QMFT) [ Time Frame: Baseline, 3, 6, 9, and 12 months ]
    The Quick Motor Function Test (QMFT) is a 16 item, psychometrically robust outcome assessment, validated in children and adults with Pompe disease (a lysosomal storage disorder characterized by progressive muscle weakness). This motor function test observes performance and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). If items can be performed on both left and right extremities, the right side is taken. A total score is obtained by adding the scores of all items. The total score ranges between 0 and 64 points. A higher score correlates with greater motor function.

  3. Change in Cognitive Function as Measured by the Vineland Adaptive Behavioral Scale [ Time Frame: Baseline, 3, 6, 9, and 12 months ]
    The Vineland-3 is a standardized measure of adaptive behavior--the things that people do to function in their everyday lives. It is a norm-based instrument that compares the examinee's adaptive functioning in four domains: Communication, Daily Living Skills, Socialization and Motor Skills to that of others of the same age. A composite score of adaptive behavior is calculated that summarizes the individual's performance across all four domains.

  4. Number of Participants With Change in Q-T Interval on ECG [ Time Frame: Baseline, 3, 6, 9, and 12 months ]
    Evidence of ECG changes, specifically, prolonged Q-T interval in response to study drug. The Q-T interval is the time from the start of the Q wave to the end of the T wave. It represents the time taken for ventricular depolarisation and repolarisation, effectively the period of ventricular systole from ventricular isovolumetric contraction to isovolumetric relaxation. Participants with a prolonged Q-T interval at any timepoint is reported.

  5. Number of Participants With Abnormal Transaminase Values [ Time Frame: Baseline, 3, 6, 9, and 12 months ]
    Transaminase values as measured by serum alanine transaminase (ALT) and aspartate transaminase (AST). Participants with abnormal transaminase values at any timepoint is reported.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   3 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 03-17years.
  • Any gender
  • Confirmed homozygotes or compound heterozygotes of pathogenic mutation variant(s) in PLA2G6
  • Confirmed homozygotes of pathogenic mutation in PLA2G6
  • Documentation of clinical presentation (signs and symptoms of neurodegenerative process) of INAD

Exclusion Criteria:

  • Patient has sign and symptom suggesting an ongoing acute or chronic illness such as fever of unknown origin or infection.
  • Patient has a second genetic condition
  • Parents are unable or unwilling to return for continued care for up to 12 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03726996

Layout table for location information
United States, North Carolina
Duke University Health Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Duke University
Layout table for investigator information
Principal Investigator: Yong-hui Jiang, MD Duke University
  Study Documents (Full-Text)

Documents provided by Duke University:
Layout table for additonal information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT03726996    
Other Study ID Numbers: Pro00100799
First Posted: November 1, 2018    Key Record Dates
Results First Posted: October 14, 2020
Last Update Posted: October 14, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Duke University:
Pediatric genetic disorder
cognitive function
neuro-muscular disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroaxonal Dystrophies
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Antidepressive Agents, Tricyclic
Antidepressive Agents
Psychotropic Drugs
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Adrenergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs